Seek Returns logo

NVDA vs. NVS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at NVDA and NVS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

NVDA is a standard domestic listing, while NVS trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

SymbolNVDANVS
Company NameNVIDIA CorporationNovartis AG
CountryUnited StatesSwitzerland
GICS SectorInformation TechnologyHealth Care
GICS IndustrySemiconductors & Semiconductor EquipmentPharmaceuticals
Market Capitalization4,240.76 billion USD245.20 billion USD
ExchangeNasdaqGSNYSE
Listing DateJanuary 22, 1999November 7, 1996
Security TypeCommon StockADR

Historical Performance

This chart compares the performance of NVDA and NVS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NVDA vs. NVS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolNVDANVS
5-Day Price Return-3.13%-0.41%
13-Week Price Return25.14%8.24%
26-Week Price Return37.55%5.12%
52-Week Price Return38.67%9.24%
Month-to-Date Return-2.07%7.80%
Year-to-Date Return29.70%14.48%
10-Day Avg. Volume193.75M2.43M
3-Month Avg. Volume190.22M3.07M
3-Month Volatility26.93%16.76%
Beta2.160.90

Profitability

Return on Equity (TTM)

NVDA

106.92%

Semiconductors & Semiconductor Equipment Industry

Max
52.74%
Q3
23.49%
Median
11.60%
Q1
3.23%
Min
-20.69%

NVDA’s Return on Equity of 106.92% is exceptionally high, placing it well beyond the typical range for the Semiconductors & Semiconductor Equipment industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

NVS

32.56%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

In the upper quartile for the Pharmaceuticals industry, NVS’s Return on Equity of 32.56% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

NVDA vs. NVS: A comparison of their Return on Equity (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

NVDA

51.69%

Semiconductors & Semiconductor Equipment Industry

Max
44.17%
Q3
22.38%
Median
11.95%
Q1
3.21%
Min
-25.16%

NVDA’s Net Profit Margin of 51.69% is exceptionally high, placing it well beyond the typical range for the Semiconductors & Semiconductor Equipment industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

NVS

24.90%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 24.90% places NVS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

NVDA vs. NVS: A comparison of their Net Profit Margin (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

NVDA

58.03%

Semiconductors & Semiconductor Equipment Industry

Max
58.03%
Q3
27.84%
Median
12.45%
Q1
5.15%
Min
-28.61%

An Operating Profit Margin of 58.03% places NVDA in the upper quartile for the Semiconductors & Semiconductor Equipment industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

NVS

30.03%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 30.03% places NVS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

NVDA vs. NVS: A comparison of their Operating Profit Margin (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolNVDANVS
Return on Equity (TTM)106.92%32.56%
Return on Assets (TTM)73.45%13.32%
Net Profit Margin (TTM)51.69%24.90%
Operating Profit Margin (TTM)58.03%30.03%
Gross Profit Margin (TTM)70.52%76.12%

Financial Strength

Current Ratio (MRQ)

NVDA

3.39

Semiconductors & Semiconductor Equipment Industry

Max
8.42
Q3
4.70
Median
2.75
Q1
2.07
Min
1.04

NVDA’s Current Ratio of 3.39 aligns with the median group of the Semiconductors & Semiconductor Equipment industry, indicating that its short-term liquidity is in line with its sector peers.

NVS

0.82

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

NVS’s Current Ratio of 0.82 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

NVDA vs. NVS: A comparison of their Current Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

NVDA

0.10

Semiconductors & Semiconductor Equipment Industry

Max
1.09
Q3
0.45
Median
0.22
Q1
0.01
Min
0.00

NVDA’s Debt-to-Equity Ratio of 0.10 is typical for the Semiconductors & Semiconductor Equipment industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NVS

0.77

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

NVS’s Debt-to-Equity Ratio of 0.77 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NVDA vs. NVS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

NVDA

75.66

Semiconductors & Semiconductor Equipment Industry

Max
174.00
Q3
81.10
Median
27.22
Q1
7.28
Min
-4.26

NVDA’s Interest Coverage Ratio of 75.66 is positioned comfortably within the norm for the Semiconductors & Semiconductor Equipment industry, indicating a standard and healthy capacity to cover its interest payments.

NVS

22.55

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

NVS’s Interest Coverage Ratio of 22.55 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

NVDA vs. NVS: A comparison of their Interest Coverage Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolNVDANVS
Current Ratio (MRQ)3.390.82
Quick Ratio (MRQ)2.860.62
Debt-to-Equity Ratio (MRQ)0.100.77
Interest Coverage Ratio (TTM)75.6622.55

Growth

Revenue Growth

NVDA vs. NVS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

NVDA vs. NVS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

NVDA

0.02%

Semiconductors & Semiconductor Equipment Industry

Max
4.16%
Q3
1.78%
Median
0.74%
Q1
0.00%
Min
0.00%

NVDA’s Dividend Yield of 0.02% is consistent with its peers in the Semiconductors & Semiconductor Equipment industry, providing a dividend return that is standard for its sector.

NVS

3.29%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

NVS’s Dividend Yield of 3.29% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

NVDA vs. NVS: A comparison of their Dividend Yield (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

NVDA

1.28%

Semiconductors & Semiconductor Equipment Industry

Max
196.12%
Q3
87.72%
Median
26.57%
Q1
0.00%
Min
0.00%

NVDA’s Dividend Payout Ratio of 1.28% is within the typical range for the Semiconductors & Semiconductor Equipment industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

NVS

102.24%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

NVS’s Dividend Payout Ratio of 102.24% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

NVDA vs. NVS: A comparison of their Dividend Payout Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolNVDANVS
Dividend Yield (TTM)0.02%3.29%
Dividend Payout Ratio (TTM)1.28%102.24%

Valuation

Price-to-Earnings Ratio (TTM)

NVDA

55.11

Semiconductors & Semiconductor Equipment Industry

Max
109.37
Q3
57.11
Median
28.95
Q1
22.13
Min
11.14

NVDA’s P/E Ratio of 55.11 is within the middle range for the Semiconductors & Semiconductor Equipment industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

NVS

17.43

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

NVS’s P/E Ratio of 17.43 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

NVDA vs. NVS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

NVDA

28.49

Semiconductors & Semiconductor Equipment Industry

Max
16.09
Q3
10.10
Median
4.82
Q1
2.60
Min
0.93

With a P/S Ratio of 28.49, NVDA trades at a valuation that eclipses even the highest in the Semiconductors & Semiconductor Equipment industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

NVS

4.34

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

NVS’s P/S Ratio of 4.34 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

NVDA vs. NVS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

NVDA

31.64

Semiconductors & Semiconductor Equipment Industry

Max
13.56
Q3
6.75
Median
3.68
Q1
1.89
Min
0.60

At 31.64, NVDA’s P/B Ratio is at an extreme premium to the Semiconductors & Semiconductor Equipment industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

NVS

6.00

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

NVS’s P/B Ratio of 6.00 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

NVDA vs. NVS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolNVDANVS
Price-to-Earnings Ratio (TTM)55.1117.43
Price-to-Sales Ratio (TTM)28.494.34
Price-to-Book Ratio (MRQ)31.646.00
Price-to-Free Cash Flow Ratio (TTM)58.7114.16